Cabaletta Bio, Inc.
HealthcareNASDAQ:CABA · NASDAQ Global Select
+$0.00 today
Vol 2.89M · Avg 3.50M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $116.6M |
| Other Current | $5.7M |
| Total Current Assets | $122.3M |
| PP&E (Net) | $20.6M |
| Other Non-current | $5.3M |
| Total Non-current Assets | $25.8M |
| Total Assets | $148.1M |
Analysis
Selected assets total $148.1M for Latest. The largest visible component is Cash & Equivalents at $116.6M, about 78.7% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $83.0M -49.4% | $164.0M -15.2% | $193.2M +136.8% | $81.6M -33.2% | $122.2M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $50.6M | $0 -100.0% | $48.0M +92.5% | $24.9M | $0 | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $0 | $0 | $0 | $0 | $0 | $533.8M | $399.4M | -$1.7B |
| Inventory | $0 | $0 | $0 | $0 | $0 | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $5.3M +94.3% | $2.7M | $0 -100.0% | $2.3M +15.9% | $2.0M | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $138.9M -16.7% | $166.7M -31.8% | $244.5M +124.6% | $108.8M -12.6% | $124.5M | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $21.1M +30.9% | $16.1M +115.8% | $7.5M -1.6% | $7.6M +426.4% | $1.4M | $1.2B | $1.5B | $687.8M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $0 | $0 | $0 | $0 | $0 | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $0 | $0 | $0 | $0 | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $5.2M -17.2% | $6.2M +264.6% | $1.7M +202.5% | $565.0K +58.3% | $357.0K | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $26.2M +17.5% | $22.3M +143.5% | $9.2M +12.6% | $8.1M +353.1% | $1.8M | -$15.3B | $14.8B | $11.3B |
| Total Assets | $165.1M -10.8% | $185.0M -27.0% | $253.7M +116.9% | $117.0M -7.4% | $126.3M | $13.3B | $11.9B | $10.6B |
| Account Payables | $6.6M +34.8% | $4.9M +8.3% | $4.5M +84.6% | $2.5M +5.6% | $2.3M | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $24.2M | $0 | $0 | $0 | $0 | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 | $0 | $0 | $0 | $0 | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $0 | $0 | $0 | $0 | $0 | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $19.3M +131.0% | $8.4M +20787.5% | $40.0K -97.0% | $1.3M -56.6% | $3.1M | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $50.2M +85.2% | $27.1M +69.4% | $16.0M +68.6% | $9.5M +13.2% | $8.4M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $2.9M | $0 | $0 | $0 | $0 | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $0 | $0 | $0 | $0 | $0 | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $2.9M -48.8% | $5.6M +285.8% | $1.5M -50.7% | $3.0M | $0 | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $53.0M +62.1% | $32.7M +87.4% | $17.5M +40.2% | $12.4M +48.5% | $8.4M | $14.7B | $3.7B | $9.6B |
| Common Stock | $1.0K +0.0% | $1.0K | $0 | $0 | $0 | $651.4M | $517.0M | $382.6M |
| Retained Earnings | -$517.0M -48.1% | -$349.1M -49.7% | -$233.2M -40.9% | -$165.6M -47.1% | -$112.6M | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | $25.0K | $0 -100.0% | $39.0K +183.0% | -$47.0K | $0 | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 -100.0% | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | $112.1M -26.4% | $152.3M -35.5% | $236.2M +126.0% | $104.5M -11.4% | $118.0M | $9.1B | $7.7B | $3.3B |
| Total Debt | $27.1M +73.7% | $15.6M +210.9% | $5.0M -2.3% | $5.1M | $0 | $724.2M | $410.6M | $399.4M |
| Net Debt | -$55.9M +62.3% | -$148.4M +21.2% | -$188.2M -146.1% | -$76.5M +37.4% | -$122.2M | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Capricor Therapeutics, Inc.
NASDAQ:CAPR
$1.18B
Allogene Therapeutics, Inc.
NASDAQ:ALLO
$463.35M
Atea Pharmaceuticals, Inc.
NASDAQ:AVIR
$359.32M
Kyverna Therapeutics, Inc.
NASDAQ:KYTX
$352.74M
Lexeo Therapeutics, Inc. Common Stock
NASDAQ:LXEO
$343.14M
Lyell Immunopharma, Inc.
NASDAQ:LYEL
$315.01M
Editas Medicine, Inc.
NASDAQ:EDIT
$244.75M
Humacyte, Inc.
NASDAQ:HUMA
$177.24M
ProQR Therapeutics N.V.
NASDAQ:PRQR
$151.72M
Immutep Limited
NASDAQ:IMMP
$53.60M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does CABA have?
Cabaletta Bio, Inc. (CABA) reported $82.98M in cash and equivalents in fiscal 2025.
How much debt does CABA carry?
Cabaletta Bio, Inc. (CABA) reported $27.10M of total debt, with net debt of -$55,884,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.